MXPA06001453A - Form of administration secured against misuse - Google Patents

Abstract

The invention relates to a form of administration which is secured against misuse and which is thermoformed without extrusion, comprising at least one synthetic or natural polymer having a resistance to breaking of at least 500 N in addition to one or several active ingredients with a misuse potential and, optionally physiologically compatible auxiliary substances. The invention also relates to a method for the production thereof.

Description

FORM OF ADMINISTRATION PROOF OF ABUSE FIELD OF THE INVENTION The present invention relates to a thermoformed administration form without abuse-proof extrusion which contains, in addition to one or more active principles (A) susceptible to abuse, as well as optionally physiologically acceptable auxiliary substances (B), less a synthetic or natural polymer (C) and optionally at least one wax (D), having the component (C), as well as the component (D) optionally each having a hardness of at least 500 N, as well as a process for the preparation of the administration form according to the invention.

BACKGROUND OF THE INVENTION Many active pharmaceutical ingredients, in addition to having an excellent activity in their field of use in question, are also susceptible to abuse, that is, they can be used by an abusive consumer to originate effects that do not correspond to their defined purpose. In this way opiates, for example, which show excellent activity to combat severe to very severe pain, are frequently used by abusive consumers to induce a state of narcosis or euphoria. In order to enable abuse, the abusive consumer breaks down the corresponding administration forms, such as tablets or capsules, for example ground in a mortar, extracts the active principle from the powder thus obtained with the help preferably of an aqueous liquid and the resulting solution , optionally after filtering through cotton or cellulose, is administered parenterally, especially intravenously. In this type of administration, compared to abusive oral administration, there is a more rapid increase in the levels of active principle producing the desired effect to the abusive consumer, that is, a "rise". This "rise" is also obtained if the powdered dosage form is administered nasally, ie, snorted. Since forms of oral administration with controlled release containing active ingredients susceptible to abuse do not usually give rise to that desired rise by the abusive consumer, even when taken orally even abusively in large quantities, such forms of administration are also finely shredded and extracted with intent to abuse. In US-A-4,070,494 it was proposed to add an inflatable agent to the administration form to prevent abuse. When water is added to extract the active ingredient, this agent swells and causes the filtrate separated from the gel to contain only a small amount of active ingredient. A corresponding principle for preventing parenteral abuse is based on the multilayer tablet described in WO 95/20947, which separately has the active substance susceptible to abuse and at least one gelling agent each in different layers. Another principle for preventing parenteral abuse is described in WO 03/015531 A2. Here, a method of administration containing an opioid analgesic and a dye as an aversive agent is described. The color released by inadmissible manipulation of the form of administration has the function of dissuading the abusive consumer from using the form of administration that has been manipulated. Another known option to hinder abuse is to add antagonists of the active ingredients to the form of administration, such as for example naloxone or naltrexone in the case of opioids, or compounds that cause a physiological defense response, such as Radix Ipecacuanha = ipecac root. But since, as in most cases of abuse, it is still necessary to spray the administration forms with an active substance suitable for abuse, it was the object of the present invention to hinder or prevent the spraying of the administration form preceding the abuse with the means normally available to a potentially abusive consumer and, in this way, provide a solid form of administration for active substances susceptible to abuse that guarantees the desired effect if administered correctly, but from which the active principles can not be converted into a form susceptible to abuse simply by spraying. This object has been solved by providing a non-extrusion-proof thermoformed administration form of abuse according to the invention, which contains, in addition to one or more active (A) susceptible to abuse, at least one synthetic or natural polymer (C) and optionally at least one wax (D), the component (C) and the component (D) optionally each having a hardness of at least 500 N. By using polymers with the minimum hardness indicated (measured as indicated in the application), preferably in such quantities that the administration form also exhibits such minimum hardness of at least 500 N, it is possible to prevent spraying of the administration form using conventional means and thereby the subsequent abuse is made difficult or is considerably prevented. . Without sufficient comminution, it is therefore not possible to administer parenterally, in particular intravenously, without risk or the extraction of the active ingredient from it takes too much time for the abusive consumer or there is no "rise" when taken orally in an abusive manner, since that a spontaneous release does not take place. According to the invention, "comminution" is understood as spraying the administration form with conventional means normally available to an abusive consumer, such as a mortar and pestle, a hammer, a mallet or other usual means for spraying the application of a force. The method of administration according to the invention is thus suitable for preventing parenteral, nasal and / or oral abuse of active ingredients, preferably pharmaceutical active substances, which are susceptible to abuse. The active pharmaceutical ingredients susceptible to abuse are known to the person skilled in the art, as well as the quantities thereof that must be used and the processes for the production thereof, and may be present as such in the administration form according to the invention, in the form of their corresponding derivatives, especially esters or ethers, or in each case in the form of corresponding physiologically acceptable compounds, especially in the form of their corresponding salts or solvates, as racemates or stereoisomers. The administration form according to the invention is also suitable for the administration of several pharmaceutical active ingredients in a form of administration. Preferably the administration form contains only a certain active principle. The administration form according to the invention is especially suitable for preventing the abuse of at least one pharmaceutical active ingredient selected from the group comprising opioids, tranquilizers, preferably benzodiazepines, barbiturates, stimulants and other narcotics. The administration form according to the invention is especially well suited to prevent the abuse of an opioid, tranquilizer or another narcotic selected from the group comprising N-. { 1- [2- (4-ethyl-5-oxo-2-tetrazolin-1-yl) ethyl] -4-methoxymethyl-4-piperidyl} propionanilide (alfentanil), 5,5-diallylbarbituric acid (allobarbital), allylprodine, alphaprodine, 8-chloro-l-methyl-6-phenyl-4H- [1,2,4] triazolo [4, 3-a] [1 , 4] -benzodiazepine (alprazolam), 2-diethylaminopropiophenone (amphephora one), (±) -a-methyl-phenethylamine (amphetamine), 2- (a-methylphenethylamino) -2-phenylacetonitrile (amphetaminil), 5-ethyl- 5-isopentylbarbituric acid (amobarbital), anileridine, apocodein, 5,5-diethylbarbituric acid (barbital), benzylmorphine, becitramide, 7-bromo-5- (2-pyridyl) -lH-1,4-benzodiazepin-2 (3H) - ona (bromazepam), 2-bromo-4- (2-chlorophenyl) -9-methyl-6H-thieno [3,2-f] [1,2,4] triazolo [4, 3-a] [1,4] diazepine (brotizolam), 17-cyclopropylmethyl-4,5a-epoxy-7a [(S) -l-hydroxy-1,2,2-trimethyl-propyl] -6-methoxy- 6, 14 -endo-ethanomorfinan-3-ol (buprenorphine), 5-butyl-5-ethylbarbituric acid (butobarbital), butorphanol, (7-chloro-l, 3-dihydro-l-methyl-2-oxo-5-phenyl-2H-1,4-benzodiazepine-3-yl) -dimethyl-carbamate (camazepam), (1S, 2S) -2-amino-1-phenyl-1-propanol (catine / D-norpseudoephedrine), 7-chloro-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-ylamin-4-oxide (chlorodiazepoxide), 7-chloro-l-methyl-5-phenyl-1H- 1, 5-benzodiazepin-2,4 (3H, 5fí) -dione (clobazam), 5- (2-chlorophenyl) -7-nitro-lH-l, 4-benzodiazepine-2 (3N) -one (clonazepam), clonitazene, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1, -benzodiazepine-3-carboxylic acid (chloracepate), 5- (2-chlorophenyl) -7-ethyl-1-methyl -lH-thieno [2,3-e] [1,4] diazepin-2 (3H) -one (clotiacepam), 10-chloro-llb- (2-chlorophenyl) -2,3,7,1-tetrahydrooxazolo [ 3, 2-d] [1,4] benzodiazepin-6 (5H) -one (cloxazolam), (-) -methyl- [3β-benzoyloxy-2β (laíf, 5aH) -tropanecarboxylate] (cocaine), 4,5a -epoxy-3-methoxy-17-methyl-7-morphinen-6a-ol (codeine), 5- (1-cyclohexenyl) -5-ethylbarbituric acid (cyclobarbital), cyclorfan, ciprenorphine, 7-chloro-5- (2 -chlorophenyl) -1H-1,4-benzodiazepine-2 (3H) -one (deloracepam), desomorphine, dextromoramide, (+) - (1-benzyl-3-dimethylamino-2-methyl-1-phenylpropyl) ropionate (dextropropoxyphene ), dez ocina, diampromide, diamorphone, 7-chloro-l-methyl-5-phenyl-lH-l, 4-benzodiazepin-2 (3H) -one (diazepam), 4, 5a-epoxy-3-methoxy-17-methyl- 6a-morphinanol (dihydrocodeine), 4,5a-epoxy-17-methyl-3, 6a-morphinenediol (dihydromorphine), dimenoxadol, dimetheptanol, dimethylthiambutene, dioxafethylbutyrate, dipipanone, (6aJ ?, 10aJ?) -6.6, 9 -trimethyl-3-pentyl-6a, 7, 8, 10a-tetrahydro-6H-benzo [c] chromen-1-ol (dronabinol), eptazocine, 8-chloro-6-phenyl-4H- [1,2,4 ] triazolo [4, 3-a] [1,4] benzodiazepine (estazolam), ethoheptacin, ethylmethylthia butene, ethyl- [7-chloro-5- (2-fluorophenyl) -2, 3-dihydro-2-oxo-1H -1, 4-benzodiazepin-3-carboxylate] (ethyl phosphate), 4,5a-epoxy-3-ethoxy-17'-methyl-7-morphinen-6a-ol (ethylmorphine), etonitazene, 4,5a-epoxy -7a- (1-hydroxy-1-methylbutyl) -6-methoxy-17-methyl-6,14-endo-ethene-morphinan-3-ol (etorphine), N-ethyl-3-phenyl-8,9, 10-trinorbornane-2-ylamine (fencamfamine), 7- [2- (a-methyl-phenethylamino) ethyl] -teophylline) (phenethylline), 3- (α-methylphenethylamino) propionitrile (fenproporex), N- (1-phenethyl-4-piperidyl) propionanilide (fentanyl), 7-chloro-5- (2-fluorophenyl) -l-methyl-1H-1, 4- benzodiazepin-2 (3H) -one (fludiazepam), 5- (2-fluorophenyl) -1-methyl-7-nitro-1H-1,4-benzodiazepin-2 (3H) -one (flunitrazepam), 7-chloro- l- (2-diethylaminoethyl) -5- (2-fluorophenyl) -lH-l, 4-benzodiazepin-2 (3H) -one (flurazepam), 7-chloro-5-phenyl-1- (2, 2, 2 -trifluoroethyl) -1H-1,4-benzodiazepin-2 (3H) -one (halazepam), 10-bramo-llb- (2-fluorophenyl) -2,3,7,11b-tetrahydro [1,3] oxazole [ 3,2-d] [1,4] benzodiazepin-6 (5H) -one (haloxazolam), heroin, 4, 5a-epoxy-3-methoxy-17-methyl-6-morphinan (hydrocodone), 4, 5a- epoxy-3-hydroxy-17-methyl-6-morphinanone (hydromorphone), hydroxypetidine, isomethadone, hydroxymethylmorphinone, ll-chloro-8, 12b-dihydro-2, 8-dimethyl-12b-phenyl-4H- [1, 3 ] oxazino [3,2-d] [1,4] benzodiazepin-4,7 (6H) -dione (ketazolam), 1- [4- (3-hydroxyphenyl) -l-methyl-4-piperidyl] -1- propanone (ketobemidone), (35,65) -6-di acetate methylamino-4, 4-diphenylheptan-3-yl (levacetylmethadol (LAAM)), (-) -6-dimethylamino-4,4-diphenyl-3-heptanone (levomethadone), (-) - 17-methyl-3-morphinananol (levorphanol), levofenacillmorphan, lofentanil, 6- (2-chlorophenyl) -2- (4-methyl-1-piperazinylmethylene) -8-nitro-2H-imidazole [1, 2-a] [1,4] -benzodiazepin-1 (4H) -one (loprazolam), 7-chloro-5- (2-chlorophenyl) -3-hydroxy-lH-l, 4-benzodiazepin-2 (3H) -one (lorazepam), 7-chloro-5- (2-chlorophenyl) -3-hydroxy-l-methyl-lH-l, 4-benzodiazepin-2 (3H) -one (lormetazepam), 5- ( 4-chlorophenyl) -2,5-dihydro-3H-imidazo [2, 1-a] isoindol-5-ol (mazindol), 7-chloro-2,3-dihydro-l-methyl-5-phenyl-lH- l, 4-benzodiazepine (edazepam), N- (3-chloropropyl) -a-methylphenethylamine (mefenorex), meperidine, 2-methyl-2-propyltrimethylene dicarbamate (meprobamate), meptazinol, metazocine, methylmorphine, α, α-dimethylphenethylamine (metamfetamine), (±) -6-dimethylamino-4, 4-diphenyl-3-heptanone (methadone), 2-methyl-3-s-tolyl-4 (3H) -quinazolinone (methaqualone), methyl- [2-phenyl-2- (2-piperidyl) acetate] (methylphenidate), 5-ethyl-l-methyl-5-phenylbarbituric acid (methylphenobarbital), 3,3-diethyl-5-methyl- 2,4-piperidinedione (metiprilone), metopon, 8-chloro-6- (2-fluorophenyl) -1-methyl-4H-imidazo [1,5-a] [1,4] benzodiazepine (midazolam), 2- ( benzhydrylsulfinyl) acetamide (modafinil), 4, 5a-epoxy-17-methyl-7-morphinen-3,6a-diol (morphine), mirofin, (±) - trans-3 - (1,1-dimethylheptyl) -7, 8, 10, 10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo [Jb, d] pyrano-9 (6aH) -one (nabilone), nalbuphine, nalorphine, narcein, nicomorphine, l-methyl- 7-nitro-5-phenyl-lH-l, 4-benzodiazepin-2 (3H) -one (nimetazepam), 7-nitro-5-phenyl-lH-l, 4-benzodiazepin-2 (3H) -one (nitrazepam) ), 7-chloro-5-phenyl-lH-l, 4-benzodiazepin-2 (3H) -one (nordazepam), norlevorphanol, 6-dimethylamino-4,4-diphenyl-3-hexanone (normetadone), normorphine, norpipanone , the coagulated sap of the plants belonging to the species Papaver somniferum (opium), 7-chloro-3-hydroxy-5-phenyl- lH-1, 4-benzodiazepin-2 (3-yl) -one (oxazepam), (cis-trans) -10-chloro-2, 3, 7, 11b-tetrahydro-2-methyl-lb-phenyloxazolo [3, 2 d] [l, 4] benzodiazepin-6- (5H) -one (oxazolam), 4,5a-epoxy-14-hydroxy-3-methoxy-17-methyl-6-morphinanone (oxycodone), oxymorphone, plants and parts of plants belonging to the species Papaver so niferum (including the subspecies setigerum), papaveretum, 2-imino-5-phenyl-4-oxazolidinone (pernoline), 1, 2, 3, 4, 5, 6-hexahidro-6, ll -dimethyl-3- (3-methyl-2-butenyl) -2,6-methane-3-benzazocin-8-ol (pentazocine), 5-ethyl-5- (1-methylbutyl) -barbituric acid (pentobarbital), ethyl- (l-methyl-4-phenyl-4-piperidinecarboxylate) (pethidine), fenadoxone, fenomorfan, phenazocine, phenoperidine, piminodine, pholcodine, 3-methyl-2-f eni lmorphine (phenmetrazine), 5-ethyl- 5-phenylbarbituric (f-enebarbital), a, -dimethyl-p-enedylamine (phentermine), 7-chloro-5-phenyl-1- (2-propynyl) -1H-1,4-benzodiazepin-2 (3H) -one (pinazepam ), a- (2-piperidyl) benzhydryl alco hol (pipradrol), l 1 - (3-cyano-3, 3-diphenylpropyl) [1,4'-bipiperidine] -4'-carboxamide (piritramide), 7-chloro-l- (cyclopropylmethyl) -5-phenyl- lH-l, 4-benzodiazepin-2 (3H) -one (prazepam), propadol, proheptazine, promedol, properidin, propoxyphene, N- (l-methyl-2-piperidinoethyl) -N- (2-pyridyl) ropionamide, methyl . { 3- [4-methoxycarbonyl-4- (N-f-enylpropanamido) piperidino] propanoate} (re if ent indigo), 5-sec-butyl-5-ethylbarbituric acid (secbutabarbital), 5-allyl-5- (1-methylbutyl) -barbituric acid (secobarbital), N-. { 4-methoxymethyl-1- [2- (2-thienyl) ethyl] -4-piperidyl} propionanilide (sufentanil), 7-chloro-2-hydroxy-methyl-5-phenyl-lH-l, 4-benzodiazepin-2 (3H) -one (temazepam), 7-chloro-5- (1-cyclohexenyl) -l -methyl-lN-1, 4-benzodiazepin-2 (3H) -one (tetrazepam), ethyl- (2-dimethylamino-l-phenyl-3-cyclohexene-1-carboxylate) (tilidine (cis and trans)), tramadol , 8-chloro-6- (2-chlorophenyl) -l-methyl-4H- [1,2,4] triazolo [4, 3-a] [1,4] enzodiazepine (triazolam), 5- (1-) acid methylbutyl) -5-vinylbarbituric (vinylbital), (1R, 2R) -3- (3-dimethylamino-l-ethyl-2-methyl-propyl) -phenol, (1R, 2R, 4S) -2- (dimethylamino) methyl-4- (p-fluorobenzyloxy) -1- (m-methoxyphenyl) cyclohexanol, (1R, 2R) -3- (2-dimethylaminomethyl-cyclohexyl) -phenol, (1S, 2S) -3- (3-dimethylamino-l-ethyl-2-methyl-propyl) -phenol, (2R, 3R) -1-dimethylamino-3 (3-methoxy-phenyl) -2-methyl-pentan -3-ol., (1RS, 3RS, 6RS) -6-dimethylaminomethyl-1- (3-methoxy-phenyl) -cyclohexane-1,3-diol, preferably as racemate, 2- (4-isobutyl-phenyl) propionate of 3- (2-dimethylaminomethyl-1-hydroxy-cyclohexyl) -phenyl, 2- (6-methoxy-naphthalen-2-yl) propionate of 3- (2-dimethylaminomethyl-1-hydroxy-cyclohexyl) phenyl, propionate 2 - (4-isobutyl-phenyl) 3- (2-dimethylaminomethyl-cyclohex-1-enyl) -phenyl, 2- (6-ethoxy-naphthalen-2-yl) propionate of 3- (2-dimethylaminomethyl-cyclohex-1) -enyl) -phenyl, 3- (2-dimethylaminomethyl-1-hydroxy-cyclohexyl) -phenyl ester of (RR-SS) -2-acetoxy-4-trifluoromethyl-benzoic acid, 3- (2-dimethylaminomethyl-1-ethyl ester) hydroxy-cyclohexyl) -phenyl acid (RR-SS) -2-hydroxy-4-trifluoromethyl-benzoic acid, 3- (2-dimethylaminomethyl-l-hydroxy-cyclohexyl) -phenyl ester of (RR-SS) -4-chloro-2-hydroxy-benzoic acid, 3- (2-dimethylaminomethyl-l-hydroxy-cyclohexyl) ester - phenyl (RR-SS) -2-hydroxy-4-methyl-benzoic acid, 3- (2-dimethylart? inomethyl-l-hydroxy-cyclohexyl) -phenyl acid ester (RR-SS) -2-hydroxy-4 -methoxy-benzoic, 3- (2-dimethylaminomethyl-l-hydroxy-cyclohexyl) -phenyl ester of (RR-SS) -2-hydroxy-5-nitro-benzoic acid, 3- (2-dimethylaminomethyl-l-hydroxy) ester -cyclohexyl) -phenyl (RR-SS) -2 ', 4' -difluoro-3-hydroxy-biphenyl-4-carboxylic acid as well as the corresponding stereoisomeric compounds, the corresponding derivatives thereof in each case, especially amides, esters and ethers, and physiologically acceptable compounds thereof in each case, especially their salts and solvates, preferring especially hydrochlorides. The administration form according to the invention is especially suitable for preventing abuse of opioid active substances selected from the group comprising oxycodone, hydromine, morphine, tramadol and physiologically acceptable derivatives or compounds thereof. themselves, preferably their salts or solvates, preferably their hydrochlorides.

In addition, the administration form according to the invention is especially suitable for preventing the abuse of an opioid active principle selected from the group comprising (IR, 2R) -3- (3-dimethylamino-l-ethyl-2-methyl-propyl) - phenol, (2R, 3R) -l-dimethylamino-3- (3-methoxy-phenyl) -2-methyl-pentan-3-ol, (1RS, 3RS, 6RS) -6-dimethylaminomethyl-1- (3-methoxy) phenyl) -cciohexane-1,3-diol, (1R, 2R) -3- (2-dimethylaminoethyl-cyclohexyl) -phenol, their physiologically acceptable salts, preferably hydrochlorides, physiologically acceptable enantiomers, stereoisomers, diastereomers, and racemates and their physiologically acceptable derivatives, preferably ethers, esters or amides. These compounds or methods of preparing them are described in EP-A-693475 or EP-A-780369. The corresponding descriptions are incorporated in this form as a reference and are considered part of the publication.

SUMMARY OF THE INVENTION In order to achieve the necessary hardness of the administration form according to the invention, at least one synthetic or natural polymer (C) is used, which has a hardness, determined using the method published in the present application, of at least 500 N. Preferably at least one polymer selected from the group comprising poly (alkylene oxides), preferably poly (methylene oxides), poly (ethylene oxides), poly (propylene oxides); polyethylene, polypropylene, polyvinyl chloride, polycarbonate, polystyrene, polyacrylate, copolymers thereof and mixtures of at least two of the polymers indicated. High molecular weight poly (alkylene oxides) thermoplastics are preferred. Especially preferred are high molecular weight poly (ethylene oxides) with a molecular weight of at least 0.5 million, preferably from at least 1 million to 15 million, determined by rheological measurements. These polymers have a viscosity of from 4500 to 17600 cP at 25 ° C, measured in an aqueous solution of 5% by weight using a Brookfield viscometer model RVF (spindle # 2 / rotational speed 2 rpm), from 400 to 4000 cP, measured in an aqueous solution of 2% by weight using the indicated viscosimeter (spindle No. 1 or 3 / rotational speed 10 rpm), or from 1650 to 10000 cP, measured in an aqueous solution of 1% by weight using the indicated viscosimeter ( spindle n ° 2 / rotational speed 2 rpm). The polymers are preferably used in powder form. They can be soluble in water.

For the rest, in order to achieve the necessary hardness of the administration form according to the invention, it is also possible to additionally use a natural or synthetic wax (D) with a hardness, measured using the method disclosed in the present application, of at least 500 N. Preferred are waxes with a softening point of at least 60 ° C. Carnauba wax and beeswax are especially preferred. More especially, carnauba wax is preferred. Carnauba wax is a natural wax, which is obtained from the leaves of the carnauba palm and has a softening point of at least 80 ° C. When the wax component is additionally used, it is used together with at least one polymer (C) in such quantities, that the administration form has a hardness of at least 500 N. Preferably component (C) is used in an amount from 35 to 99.9% by weight, especially preferably at least 50% by weight, very especially preferably at least 60%, based on the total weight of the administration form. As auxiliary substances (B), the conventional auxiliary substances known for the formulation of solid administration forms can be used. Preferably these are softening agents, such as polyethylene glycol, auxiliary substances that influence the release of active principle, preferably hydrophobic or hydrophilic polymers, especially hydrophilic, very particularly preferably hydroxypropylcellulose, and / or antioxidants. Suitable antioxidants are ascorbic acid, butylhydroxyanisole, butylhydroxytoluol, salts of ascorbic acid, monothioglycerin, phosphorous acid, vitamin C, vitamin E and its derivatives, sodium bisulfite, especially preferable butylhydroxytoluol (BHT) or butylhydroxyanisole (BHA) and α-tocopherol. The antioxidant is preferably used in an amount of from 0.01 to 10% by weight, preferably from 0.03 to 5% by weight, based on the total weight of the administration form. The administration forms according to the invention are distinguished in that, due to their hardness, they can not be pulverized with the help of conventional grinding media within reach of the abusive consumer such as a mortar and pestle. This practically eliminates oral, parenteral abuse, especially intravenous or nasal abuse. However, in order to prevent any possible abuse of the administration form according to the invention, the administration forms may contain, in a preferred embodiment, other agents that hinder or prevent the abuse as auxiliary substances (B).

In this way, the abuse-proof administration form according to the invention, which has, in addition to one or more active substances susceptible to abuse, at least one polymer (C) hardener and optionally at least one wax (D), and still at least one of the following components (a) - (e) as auxiliary substances (B): (a) at least one substance that irritates the nostrils and / or pharynx, (b) at least one agent that increases viscosity, which, with the help of a minimum necessary amount of an aqueous liquid, forms a gel from the administration form which preferably remains visually distinguishable when added to an additional amount of aqueous liquid, (c) at least one antagonist for each of the susceptible active ingredients of abuse, (d) at least one emetic, (e) at least one dye as an aversive agent, (f) at least one bitter substance. The components (a) to (f) are each individually suitable to further protect the administration form according to the invention from abuse. Accordingly, component (a) is preferably suitable to protect the administration form from abuse by nasal, oral and / or parenteral route, preferably intravenously, component (b) preferably for parenteral abuse, especially preferably for intravenous and / or nasal abuse, component (c) preferably for nasal and / or parenteral abuse, especially preferable for intravenous abuse, component (d) preferably for parenteral abuse, especially preferably intravenously and / or orally and / or nasally abused, component (e) as a visual repellent for oral or parenteral abuse, and component (f) for oral or nasal abuse. By the combined use according to the invention of at least one of the components indicated above, the abuse of administration forms according to the invention is made even more difficult. In one embodiment, the administration form according to the invention can also have two or more of the components (a) - (f) in a combination, preferably (a), (b) and optionally (c) and / or (f) and / or (e), or (a), (b) and optionally (d) and / or (f) and / or (e). In another embodiment, the administration form according to the invention can have all the components (a) - (f). If the method of administration according to the invention encompasses component (a) to prevent abuse, all those substances according to the invention which, when administered correspondingly via the pits, are considered as substances irritating the nasal passages and / or the pharynx. nasal and / or pharynx, generate a physical reaction which is either so unpleasant for the abusive consumer who does not want or can not continue with the administration, for example stinging, or otherwise counteract in a physiological way the assimilation of the active principle corresponding, for example due to increased nasal secretion or sneezing. Those substances that conventionally irritate the nostrils and / or pharynx can also cause a very unpleasant sensation or even an unbearable pain when administered parenterally, especially intravenously, in such a way that the abusive consumer does not want or can not continue taking the substance . Especially suitable irritants of the nasal passages and / or pharynx are those substances that cause stinging, itching, the urge to sneeze, an increase in secretions or a combination of at least two of these stimuli. The corresponding substances and the amounts thereof which are conventionally used are well known to the person skilled in the art or can be identified by means of simple preliminary tests.

The irritating substance of the nostrils and / or the pharynx of component (a) is preferably based on one or more constituents or one or more parts of plants, of at least one drug with spicy substances. The corresponding drugs with spicy substances are known to the person skilled in the art and are described, for example, in "Pharmazeutische Biologie - Drogen und ihre Inhaltsstoffe" by Professor Dr. Hildebert Wagner, 2nd revised edition, Editorial Gustav Fischer, Stuttgart-New York, 1982, pages 82 and the following. The corresponding description is incorporated in this way as a reference and is considered part of the publication. As administration unit is meant a separate or separable administration unit, such as for example a tablet or a capsule. Preferably one or more drug constituents with spicy substances, selected from the group consisting of Allii satyb Bulbus, Asar and Rhomaoma c., Can be added as component (a) to the administration form according to the invention. Herba, Calami Rhizoma, Capsici Fructus (pepper), Capsici Fructus acer (chilli pepper), Curcumae longae Rhizoma, Curcumae xanthorrhizae Rhizoma, Galangae Rhizoma, Myristicae Semen, Piperis nigri Fructus (pepper), Sinapis albae (Erucae) Semen, Sinapis nigri Semen, Zedoariae Rhizoma and Zingiberis Rhizoma, especially preferable from the group consisting of Capsici Fructus (pepper), Capsici Fructus acer (chilli pepper) and Piperis nigri Fructus (pepper). The constituents of the drugs with spicy substances are preferably o-methoxy (methyl) -phenol compounds, acid amide compounds, mustard essences or sulfur compounds or compounds derived therefrom. Especially preferred is at least one constituent of the drugs with spicy substances, selected from the group consisting of myristicin, elemycin, isoeugenol, β-asarone, safrole, gingerols, xanthorizol, capsaicinoids, preferably capsaicin, capsaicin derivatives, such as N-vanillyl- 9E-octadecenamide, dihydrocapsaicin, nordihydrocapsaicin, homocapsaicin, norcapsaicin and nomorcapsaicin, piperine, preferably trans-piperine, glucosinolates, preferably based on non-volatile essences of mustard, especially preferably based on mustard essence with p-hydroxybenzyl substituents, mustard essence with methylmercapto substituents or mustard essence with methylsulfonyl substituents, and compounds derived from these constituents. Preferably, the administration form according to the invention can contain the plant parts of the drugs with corresponding spicy substances in an amount of 0.01 to 30% by weight, especially preferably 0.1 to 0.5% by weight, in relation to the total weight of the administration unit in each case. If one or more constituents of the drugs with spicy substances are used, the amount thereof in a delivery unit according to the invention is preferably raised from 0.001 to 0.005% by weight, based on the total weight of the administration unit. Another option to prevent abuse of the administration forms according to the invention is to add to the administration form at least one agent that increases the viscosity as additional compound (b) to prevent abuse, which, with the aid of a minimum amount The required aqueous liquid, preferably as an aqueous extract obtained from the form of administration, forms a gel, which can hardly be administered without danger and which remains visually distinguishable when added to a further amount of aqueous liquid. For the purpose of the present invention, visually distinguishable means that the gel containing the active ingredient, formed with the aid of a minimum necessary amount of aqueous liquid, when introduced, preferably with the aid of a hypodermic needle, in an additional amount of aqueous liquid at 37 ° C, remains essentially insoluble and cohesive and can not be easily dispersed, so that a parenteral administration, especially intravenous, without danger is impossible. Preferably the duration of the visual distinction amounts to at least one minute, preferably at least 10 minutes. Increasing the viscosity of the extract makes it more difficult or "even impossible to pass it through a needle or inject it." If the gel continues to be visually distinguishable, this means that the gel obtained by introducing a further amount of aqueous liquid, for example by injection into blood, initially continues in the form of a highly continuous thread, which although in fact can be broken into small fragments by mechanical action, it can not be dispersed or even dissolved, so that a parenteral administration, especially intravenous, without danger is impossible. In combination with at least one component (a) to (e) optionally present, this additionally results in unpleasant stinging, vomiting, bad taste and / or visual disgust. An intravenous administration of a corresponding gel would most likely result in an obstruction of the blood vessels, associated with serious damage to the health of the abusive consumer. In order to verify whether the viscosity-increasing agent is suitable as component (b) for use in the administration form according to the invention, the active ingredient is mixed with the viscosity-increasing agent and is suspended in 10 ml of water at a temperature of 25 ° C. If this results in the formation of a gel that meets the conditions mentioned above, the agent that increases the corresponding viscosity is suitable to prevent or further prevent abuse of the administration forms according to the present invention. If component (b) is added to the administration form according to the invention, preferably one or more viscosity-increasing agents are selected from the group comprising microcrystalline cellulose with 11% by weight of sodium carboxymethylcellulose (Avicel "RC591), sodium carboxymethylcellulose (Blanose®, CMC-Na C300P81, Frimulsion BLC-5®, Tylose C300 PT), polyacrylic acid (Carbopol8"980 NF, CarbopolF 981), carob bean meal (Cesagum 'LA-200, Cesagum' LID / 150, Cesagum LN-1), pectins, preferably citrus or apple (Cesapectin "HM Medium Rapid Set), waxy corn starch (C * Gel 04201), sodium alginate (Frimulsion ALG (E401) *), guar seed flour (Frimulsion BM ", Polygum 26 / 1-75), iota-carrageenan (Frimulsion D021?), Karaya gum, gellan gum (Kelcogel F®, Kelcogel LTIOO®), galactomannan (Meyprogat 150 @), tara seed meal (Polygum 43 / lT), propylene glycol alginate (Protanal-Ester SD-LB), sodium hyaluronate, tragacanth, tara gum (Vidogum SP 200 '), fermented polysaccharides of welan gum (1A96) and xanthan gum (Xantural 180®). Xantans are especially preferred. The names indicated in parentheses are the registered trademarks for which the materials are commercially known. In general, an amount of the agent (s) which increases the indicated viscosity (s) from 0.1 to 20% by weight, especially preferably from 0.1 to 15% by weight, based on with the total weight of the administration form, it is sufficient to meet the conditions indicated above. Agents that increase the viscosity of component (b), if provided, are preferably present in the administration form according to the invention in amounts = 5 mg per administration unit, ie for each dosage unit. In an especially preferred embodiment of the present invention, those agents that increase the viscosity are used as component (b) which, by extraction of the form of administration with the minimum necessary amount of an aqueous liquid, form a gel containing air bubbles . The gels resulting in this way are distinguished by a cloudy appearance, by which the potentially abusive consumer is further warned optically and deters him from parenteral administration. The component (C) can also optionally serve as an additional agent which increases the viscosity, which forms a gel with the aid of a minimum necessary quantity of aqueous liquid. It is also possible to formulate the agents which increase the viscosity and the remaining constituents in the administration form according to the invention in such an arrangement that they are spatially separated from one another. For the rest, in order to prevent and protect the abuse, the administration form according to the invention can also have the component (c), that is, one or more antagonists for the active principle or active substances susceptible to abuse, the antagonists spatially separated from the remaining constituents of the administration form according to the invention and, with an appropriate use of the administration form, produce no effect. Suitable antagonists for preventing the abuse of the active ingredients are known to the person skilled in the art and can be present in the administration form according to the invention as such, or in the form of their corresponding derivatives, especially esters or ethers, or in each case in the form of the corresponding physiologically acceptable compounds thereof, especially in the form of their salts or solvates. If the active ingredient present in the administration form is an opioid, the antagonist used is preferably an antagonist selected from the group comprising naloxone, naltrexone, nalmefene, nalid, nalmexone, nalorphine or nalbuphine, in each case optionally in the form of a physiologically acceptable, especially in the form of a base, a salt or solvate. When a preparation with component (c) is provided, the corresponding antagonists are preferably used in an amount of > 1 mg, especially preferable in an amount of from 3 to 100 mg, very especially preferable in an amount of from 5 to 50 mg per each administration form, ie for each dosage unit.

If the administration form according to the invention contains a stimulant as active ingredient, the antagonist is preferably a neuroleptic, preferably at least one compound selected from the group consisting of haloperidol., promethazine, flufenacin, perphenazine, levomepromazine, thioridazine, perazine, chlorpromazine, chlorprothixene, zuclopenthixol, flupentixol, protipendil, zotepine, behperidol, pipamperone, melperone and bromoperidol. Preferably the administration form according to the invention contains these antagonists in a conventional therapeutic dose known to the person skilled in the art, especially preferably in an amount of two to three times the conventional dose for each dosage unit. If the combination for preventing and protecting the abuse of the administration form according to the invention comprises the component (d), this may have at least one emetic, which is preferably in a spatially separate arrangement from the remaining constituents of the form of administration according to the invention and, with an appropriate use of the administration form, should not produce any effect in the organism. Emetics suitable for preventing the abuse of an active ingredient are known to the person skilled in the art and can be present in the administration form according to the invention as such, or in the form of their corresponding derivatives, in particular esters or ethers, or in each case in the form of the corresponding physiologically acceptable compounds, in particular in the form of their salts or solvates.

In the administration form according to the invention, an emetic based on one or more constituents of Radix Ipecacuanha (ipecacuanha root), preferably based on the emetine constituent, as described, for example, in "Pharmazeutische Biologie - Drogen und ihre Inhaltsstoffe" may be preferred. "by Professor Dr. Hildebert Wagner, 2nd revised edition, Editorial Gustav Fischer, Stuttgart-New York, 1982. The corresponding bibliographic description is incorporated in this form as a reference and is considered part of the publication. Preferably the administration form according to the invention can have the emetic emetine as component (d), preferably in an amount of > 3 mg, especially preferably from > 10 mg and very especially preferable in an amount of > 20 mg per each administration form, that is, per dosage unit. Likewise, apomorphine can be preferably used as an emetic in the protection against abuse according to the invention, preferably in an amount of preferably > 3 mg, especially preferably from > 5 mg and very especially preferable of > 7 mg for each dosage unit. If the administration form according to the invention contains a component (e) as an additional auxiliary substance for the prevention of abuse, the use of such dyes causes an intense coloration of the corresponding aqueous solution, especially when trying to extract the active ingredient for an administration parenteral, preferably intravenous, which can act as a repellent for the potentially abusive consumer. Oral abuse, which conventionally begins by means of an aqueous extraction of the active principle, can also be prevented by this coloring. Suitable colorants and the amounts required for the necessary repellent effect can be taken from WO 03/015531, considering the corresponding publication as part of the present publication and incorporating it in this way as a reference. If the administration form according to the invention contains the component (f) as an additional auxiliary substance to prevent abuse, oral and / or nasal abuse is further prevented by this addition of at least one bitter substance by consequent damage to the taste of the form of administration that appears in this way. Suitable bitter substances can be taken as well as the amounts effective for use of US-2003/0064099 Al, the corresponding publication of which should be considered as publication of the present application and incorporated in this way as a reference.

Bitter substances preferably are aromatic essences, preferably peppermint oil, eucalyptus oil, bitter almond oil, menthol, fruit aromatic substances, preferably aromatic substances of lemons, oranges, limes, grapefruit or mixtures thereof, and / or denatonium benzoate (Bitrex ") Denatonium benzoate is especially preferred The solid administration form according to the invention is suitable for oral, vaginal or rectal administration, preferably orally. Laminar form The administration form according to the invention can be present in the form of multiple particles, preferably in the form of micro-tablets, microcapsules, micro-pellets, granules, spheroids, beads or pellets, optionally introduced in capsules or compressed tablets, preferably for application by orally, preferably multi-particle forms they have a size or a size distribution in the range of from 0.1 to 3 mm, especially preferably in the range of 0.5 to 2 mm. Depending on the desired administration form, conventional auxiliary substances (B) are optionally also used for the formulation of the administration form. The abuse-resistant solid administration form according to the invention is preferably prepared without the use of an extruder, such that preferably the components (A), (B), (C) and the component (D) optionally present and optionally at least one of the additional components (a) - (f) optionally present, are mixed together or , if necessary, they are mixed separately with addition of the component (C) and optionally of the component (D) and the resulting mixture or resulting mixtures, optionally after a granulation, is modeled by pressure, under exposure to the preceding heat or simultaneous, to give rise to the form of administration. This exposure to heat and pressure for the preparation of the administration form is carried out without the use of an extruder. The mixture of the components (A), (B), (C) and optionally (D), as well as either of the components (a) - (f) optionally present and optionally of the component (C) and the component (D) optionally present, optionally takes place for each one in a mixing equipment known to the person skilled in the art. The mixing equipment can be for example a roller mixer, a stirring mixer, a shear force mixer, or an Eirich type mixer. The resulting mixture or the resulting mixtures are preferably modeled directly by application of pressure, under exposure to the previous or simultaneous heat, to give rise to the administration form according to the invention. The mixture can, for example, be molded into tablets by direct compression. In a direct compression under simultaneous exposure to heat, the mixture is heated with the aid of the compression instruments, ie the lower mold, the upper mold and the matrix, at least up to the softening point of the polymer (C), and Same time is compressed. In a direct compression under pre-heat exposure, the material to be compressed is heated immediately before compression to at least the softening temperature of the component (C) and then compressed with the aid of compression equipment. The resulting mixture of components (A), (B), (C) and optionally (D) as well as components (a) to (f) optionally present or of the mixture of at least one of those components (a) a (f) with the component (C), it can be granulated first and then molded by pressure, under exposure to the previous or simultaneous heat, to give rise to the administration form according to the invention.

Each time a pressure is exerted, this pressure is maintained until the administration form reaches a hardness of at least 500 N.

The granulation can be carried out by wet granulation or by melting in known granulators. Each of the steps of the process indicated, especially heating and simultaneous or subsequent pressure, for the preparation of the administration form according to the invention is carried out without the use of an extruder. In another preferred embodiment, the administration form according to the invention is in the form of a tablet, a capsule, or in the form of an oral osmotic therapeutic system (OROS), preferably when at least one additional component to prevent abuse (a) a (f) is present. If the components (c) and / or (d) and / or (f) are present in the administration form according to the invention, it should be taken into account that they are formulated or dosed scarcely in such a way that when the administration form is administered correctly, they can practically not show any effect that could affect the patient or the efficacy of the active principle. If the administration form according to the invention contains the component (d) and / or (f), the dosage has to be selected in such a way that when administered orally correctly, it does not cause any negative effect. If, however, the expected dosage is exceeded in case of abuse, nausea or a vomiting impulse or a bad taste occurs. The particular amount of component (d) and / or (f), which is still tolerable for the patient in the case of a correct oral administration, can be determined by simple preliminary tests by a person skilled in the art. If, however, regardless of the fact that the administration form according to the invention is practically impossible to spray, the use of the components (c) and / or (d) and / or (f) for the protection of the shape is envisaged. of administration, these components should preferably be used in sufficiently high dosages so that, when the administration form is administered in an abusive manner, they give rise to intense negative effects for the abusive consumer. This is preferably achieved by spatial separation of at least the active principle or active ingredients of the components (c) and / or (d) and / or (f), the active ingredient or the active ingredients being found in at least one subunit (X) and the components (c) and / or (d) and / or (f) are found in at least one subunit (Y), and not showing the components (c), (d) and (f) when the administration form is correctly administered its effect during the intake and / or in the organism and the rest of the compounds of the formulation, especially the component (C) and optionally ( D), identical. If the administration form according to the invention has at least two of the components (c), and (d) or (f), these can each be in the same or in different subunits (Y). Preferably, if present, all components (c) and (d) and (f) are in one and the same subunit (Y). Subunits in the sense of the present invention, are solid formulations, which in each case, apart from the conventional auxiliary substances known to the person skilled in the art, contain the active principle (s), at least one polymer (C) and component (D) optionally present and optionally at least one of components (a) and / or (b) and / or (e) optionally present, or in each case at least one polymer (C) and optionally (D) and the antagonist (s) and / or the emetic (s) and / or the component (e) and / or the component (f) and optionally at least one of the components (a) ) and / or (b) optionally present. Here it must be taken into account, that each one of the mentioned subunits is formulated according to the procedure indicated above. A substantial advantage of the separate formulation of the active ingredients of the components (c) or (d) or (f) in subunits (X) and (Y) of the administration form according to the invention is thatwhen it is administered correctly, the components (c) and / or (d) and / or (f) during the taking and / or in the organism are practically not released, or are only released in such small amounts, that they do not produce harmful effect on the patient or therapeutic success, or that during the passage through the patient's body are only released in the places of release, where they can not be sufficiently absorbed to be effective. Preferably, the components (c) and / or (d) and / or (f) are practically not released in the patient's body or go unnoticed by the patient when the administration form is correctly administered. The person skilled in the art understands that the conditions indicated above may vary depending on the particular components (c), (d) and / or (f) used, as well as the formulation of the subunits or the method of administration. The optimal formulation for each particular administration form can be determined by simple preliminary tests. What is vital is that each subunit contains the polymer (C) and optionally the component (D) and has been formulated in the manner indicated above. In the event that the abusive consumer, contrary to expectations, manages to shred a form of administration according to the invention having the components (c) and / or (e) and / or (d) and / or (f) in subunits (Y), for the purpose of an abusive taking of the active principle and obtain a powdery solid, which is extracted with a suitable extraction medium, is obtained in addition to the active principle, also the component (c) and / or (e) and / or (f) and / or (d) particular in a form in which it can not be easily separated from the active principle; so that when the administration form, which has been manipulated, is administered, in particular orally and / or parenterally, it will show its effect during the intake and / or in the organism combined with an additional negative effect for the corresponding abusive consumer to one of the components (c) and / or (d) and / or (f) or, when attempting to extract the active ingredient, the coloring will act as a repellent and will prevent the abuse of the form of administration. The formulation of a method of administration according to the invention, in which the active principle or the active ingredients are spatially separated from the components (c), (d) and / or (e), preferably by the formulation in different subunits can be carried out in many different ways, the corresponding subunits in the form of administration according to the invention being able to be found with respect to each other in any spatial arrangement, provided that the conditions indicated above for the release of the components (c ) and / or (d) are met. The person skilled in the art understands that the component (s) (a) and / or (b) optionally present, can be formulated preferably in the administration form according to the invention both in the particular subunits (X) and (Y) as in the form of independent subunits corresponding to subunits (X) and (Y), provided that neither the protection of the form of administration against abuse nor the release of active principle, in the case of correct administration, are affected by the nature of the formulation and that the polymer (C) and optionally (D) is included in the formulation and the formulation is carried out according to the procedure indicated above to achieve the necessary hardness. In a preferred embodiment of the administration form according to the invention, the subunits (X) and (Y) are in the form of multiple particles, with microcompressed, microcapsules, micropelets, granules, spheroids, beads or pellets being preferable, and selecting for the subunit (X) as well as for the subunit (Y) the same form, ie configuration, so that it is not possible to separate the subunits (X) from (Y), for example by mechanical selection. The multi-particle forms preferably have a size of from 0.1 to 3 mm, preferably from 0.5 to 2 mm. The subunits (X) and (Y) in the form of multiple particles can preferably be introduced into a capsule or injected into a tablet, the final formulations taking place in each case so that the subunits (X) and (Y) are maintained in the resulting form of administration. The particular subunits (X) or (Y) in the form of multiple particles with identical configuration should not be visually distinguishable from one another, so that the abusive consumer can not separate them from one another by a simple classification. This can, for example, be achieved by application of identical covers, which, apart from this egalitarian function, can also have additional functions, such as, for example, the delayed release of one or more active ingredients or provide each of the Subunits with a finish resistant to gastric juices. The subunits in the form of multiple particles can also be formulated as an aqueous suspension or as a suspension in harmless pharmaceutical suspension media as oral administration forms.

In another preferred embodiment of the present invention, the subunits (X) and (Y) are arranged one with respect to the other in layers. The subunits (X) and (Y) in layers are preferably arranged horizontally or vertically for this purpose with respect to one another in the administration form according to the invention, wherein one or more subunits (X) can be present in layers and one or more subunits (Y) in layers, in the administration form, so that, apart from the preferred layer sequences (X) - (Y) or (X) - (Y) - (X), it can be taken in any other desired sequence, optionally in combination with layers containing the components (a) and / or (b). Also preferred is an administration form according to the invention, in which the subunit (Y) forms a core that is completely enveloped by the subunit (X), there may be between these layers a separation layer (Z). A corresponding structure is also preferably suitable for the multi-particle forms indicated above, both subunits (X) then being (Y), as well as a separation layer optionally present (Z), which have to satisfy the hardness requirements according to the invention, are formulated in one and the same multi-particle form. In another preferred embodiment of the administration form according to the invention, the subunit (X) forms a core, which is surrounded by the subunit (Y), the latter having at least one channel leading from the nucleus to the surface of the form of administration. The administration form according to the invention can contain, between a layer of the subunit (X) and a layer of the subunit (Y), in each case, one or more, preferably an optionally swellable separating layer (Z) for spatially separating the subunit (X) of (Y). If the administration form according to the invention has the subunits (X) and (Y) in layers, as well as a separation layer (Z) optionally present in an at least partially vertical or horizontal arrangement, the administration form preferably has the form of a tablet or a laminate. In this case, in a particularly preferred embodiment, all of the free surfaces of the subunit (Y) and optionally at least part of the free surface of the subunit (s) (X) and optionally at least part of the Free surface of the separation layer (Z) optionally present, can be covered by at least one barrier layer (Z '), which prevents the release of component (c) and / or (e) and / or (d) I f) . The barrier layer (Z ') must also comply with the hardness conditions according to the invention.

An embodiment of the administration form according to the invention having a vertical or horizontal arrangement of the layers of the subunits (X) and (Y) and at least one layer (p) of push ("push layer") is also especially preferred. placed between them, as well as optionally a separation layer (Z), in which all the free surfaces of the layer structure, consisting of the subunits (X) and (Y), the push layer and the layer ( Z) of separation optionally present, is provided with a semipermeable cover (E), which is permeable to the release means, i.e., conventionally a physiological liquid, essentially impermeable to the active ingredient and to component (c) and / or (d) and / or (f), and this cover (E) having at least one opening for the release of the active principle in the area of the subunit (X) - A corresponding administration form is known to the person skilled in the art, for example under the name of oral osmotic therapeutic system (OROS), as well as the materials and methods suitable for the preparation thereof, among others. of the documents US 4,612,008, US 4,765,989 and US 4,783,337 among others. The corresponding descriptions are incorporated in this way as a reference and are considered part of the publication.

In another preferred embodiment, the subunit (X) of the administration form according to the invention has the form of a tablet, whose lateral edge and optionally one of the two main faces is covered with a barrier layer (Z ') containing the component (c) and / or (d) and / or (f). The person skilled in the art understands that the auxiliaries of the subunit (s) (X) or (Y), as well as the separation layer (s) (Z) optionally present and / or the (s) ) Barrier layer (s) (Z ') used in each case to formulate the administration form according to the invention vary depending on the arrangement thereof in the administration form according to the invention, the mode of administration as well as in function of the particular active ingredient of optionally present components (a) and / or (b) and / or (e) and of component (c) and / or (d) and / or (f). The materials, which have the properties required in each case are known per se by the person skilled in the art.

If the release of component (c) and / or (d) and / or (f) from the subunit (Y) of the administration form according to the invention is prevented with the aid of a cover, preferably a barrier layer , the subunit may consist of conventional materials known to the person skilled in the art, provided that it contains at least one polymer (C) and optionally (D) to meet the hardness condition of the administration form according to the invention.

If a corresponding barrier layer (Z ') is not provided to prevent the release of the component (c) and / or (d) and / or (f), the materials of the subunits must be selected in such a way that the release of the particular component (c) and / or (d) from the subunit (And) practically discarded. The materials indicated below, which are also suitable for the production of the barrier layer, can be used for this purpose. Preferred materials are those selected from the group comprising alkylcelluloses, hydroxyalkylcelluloses, glucans, scleroglucans, mannans, xanthans, copolymers of poly [bis (p-carboxyphenoxy) propane and sebacic acid, preferably in a molar ratio of 20:80 (commercially available under the name of Polifeprosan 20), carboxymethylcelluloses, cellulose ethers, cellulose esters, nitrocelluloses, polymers based on methacrylic acid, as well as the esters thereof, polyamides, polycarbonates, polyalkylenes, polyalkylene glycols, poly (alkylene oxides), poly (terephthalates) alkylene), poly (vinyl alcohols), poly (vinyl ethers), poly (vinyl esters), halogenated polyvinyls, polyglycolides, polysiloxanes as well as polyurethanes and the copolymers thereof.

Particularly suitable materials may be selected from the group comprising methylcellulose, ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxybutylmethylcellulose, cellulose acetate, cellulose propionate (low, medium or high molecular weight), cellulose acetate propionate, cellulose acetate butyrate, acetate -cellulose phthalate, carboxymethylcellulose, cellulose triacetate, sodium cellulose sulfate, poly (methyl methacrylate), poly (ethyl methacrylate), poly (butyl methacrylate), poly (isobutyl methacrylate), poly (hexyl methacrylate) , poly (isodecyl methacrylate), poly (lauryl methacrylate), poly (phenyl methacrylate), poly (methyl acrylate), poly (isopropyl acrylate), poly (isobutyl acrylate), poly (octadecyl acrylate), polyethylene, low density polyethylene, high density polyethylene, polypropylene, polyethylene glycol, poly (ethylene oxide), poly (ethylene terephthalate), poly (vinyl alcohol) ico), poly (vinyl isobutyl ether), poly (vinyl acetate) and poly (vinyl chloride). Especially suitable copolymers can be selected from the group comprising copolymers of butyl methacrylate and isobutyl methacrylate, copolymers of methyl vinyl ether and of high molecular weight maleic acid, copolymers of methyl vinyl ether and of monoethyl ester of maleic acid, copolymers of methyl vinyl ether and maleic anhydride as well as copolymers of vinyl alcohol and vinyl acetate. Other materials especially suitable for formulating the barrier layer are polycaprolactones filled with starch (WO98 / 20073), aliphatic poly (ester amides) (DE 19 753 534 Al, DE 19 800 698 A1, EP 0 820 698 Al), aliphatic and aromatic polyester-urethanes (DE 19822979), polyhydroxyalkanoates, especially polyhydroxybutyrates, polyhydroxyvalerate, casein (DE 4 309 528), polylactides and copolylactides (EP 0 980 894 Al ). The corresponding descriptions are entered in this way as a reference and are considered part of the publication. The materials indicated above can optionally be mixed with other conventional auxiliary substances known to the person skilled in the art, preferably selected from the group comprising softening agents, lubricants, antioxidants, such as for example glycerin monostearate, semisynthetic triglyceride derivatives, semi-synthetic glycerides, oil hydrogenated castor bean, glycerin palmito stearate, glycerin behenate, poly (vinylpyrrolidone), gelatin, magnesium stearate, stearic acid, sodium stearate, talc, sodium benzoate, boric acid and colloidal silica, fatty acids, substituted triglycerides, glycerides, polyoxyalkylene glycols, polyalkylene glycols and the compounds derived therefrom. If the administration form according to the invention has a separation layer (Z '), said layer, as well as the uncoated subunit (Y), can preferably be formed by the materials indicated above for the barrier layer. The person skilled in the art understands that the release of the active principle or component (c) and / or (d) from the particular subunit can be controlled by the thickness of the separation layer. The administration form according to the invention has a release of the active principle in a controlled manner. Of * this way it is preferably suitable for a twice-a-day administration to patients. The administration form according to the invention may have one or more active substances which are at least partially abused in the form of an additionally delayed release, the controlled release being possible with the aid of conventional materials and processes known to the person skilled in the art, for example by means of inclusion of the active ingredient in a controlled release matrix or by the application of one or more controlled release covers. The release of the active principle must, however, be controlled in such a way that the conditions indicated above are met in each case, for example that, in the case of a correct administration of the administration form, the active principle or the active principles they are virtually completely released before component (c) and / or (d) optionally present can produce a detrimental effect. In addition, the supplement of retardant materials must not cause any damage to the necessary hardness. The controlled release from the administration form according to the invention is preferably achieved by the inclusion of the active ingredient in a matrix. The auxiliary substances that act as matrix materials control the release of the active principle. Matrix materials can be, for example, hydrophilic gel-forming materials, from which the release of active principle takes place mainly by diffusion, or hydrophobic materials, from which the release of active principle takes place mainly by diffusion through the pores of the matrix. Physiologically acceptable hydrophilic materials that are known to those skilled in the art can be used as matrix materials. Polymeric hydrophilic matrix materials are preferably used, especially preferably cellulose ethers, cellulose esters and / or acrylic resins. As matrix materials, ethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxymethylcellulose, poly (meth) acrylic acid and / or the derivatives thereof, such as the salts, amides or esters thereof, are most preferably used. Also preferred are matrix materials formed from hydrophobic materials such as hydrophobic polymers, waxes, fats, long chain fatty acids, fatty alcohols or corresponding esters or ethers or mixtures thereof. Particular preference is given to using mono- or diglyceride hydrophobic materials of _2-C30 fatty acids and / or C2-C30 fatty alcohols and / or waxes or mixtures thereof. It is also possible to use mixtures of the hydrophilic and hydrophobic materials indicated above as matrix materials. Otherwise, the components (C) and the component (D) optionally present, which serve to achieve the hardness of at least 500 N necessary according to the invention, can already serve as additional matrix materials. If the administration form according to the invention is intended for oral administration, it may preferably have a coating that is resistant to gastric juices, which dissolves depending on the pH of the release site. Through this cover, it is possible to achieve that the administration form according to the invention passes through the stomach without dissolving and that the active principle is not released into the intestine. The gastric juice-resistant coating is preferably dissolved at a pH value between 5 and 7.5. Materials and corresponding procedures for the controlled release of active ingredients as well as for the application of gastric juice-resistant coatings are known to the person skilled in the art, for example from "Coated Pharmaceutical Dosage Forms Fundamentals, Manufacturing Techniques, Biopharmáceutical Aspects, Test Methods and Raw Materials "by Kurt H. Bauer, K. LeJhmann, Hermann P. Osterwald, Rothgang, Gerhart, Ia Edition, 1998, Medpharm Scientific Publishers. The corresponding bibliographic description is incorporated in this way as a reference and is considered part of the publication.

Method for the determination of the hardness In order to verify whether a material can be used as component (C) or (D), the material is injected into a tablet with a diameter of 10 mm and a height of 5 mm using a force of 150 N, at a temperature that corresponds at least to the softening temperature of the material and determined with the aid of the differential scanning calorimetry (DSC) diagram of the injected material. With the tablets prepared in this way, the hardness is determined with the use of the apparatus described below according to the method for the determination of the hardness of tablets published in the European Pharmacopoeia 1997, page 143,144, method No. 2.9.8. As an apparatus A material testing machine of the signature Z ick "Z ick Z 2.5" is used, material testing machine with a maximum force of 2.5 kN with a maximum transverse travel of 1150 mm, which is graduated by a construction with the help of a column and a screw, a free backward working space of 100 mm and an adjustable test speed of between 0.1 to 800 mm / min and a software program: testControl. A piston with threaded parts and a cylinder (diameter 10 mm), an exerted force gauge, 1 kN maximum force, 8 mm diameter, class 0.5 from 10 N, class starting from 2 N are used according to ISO 7500-1, with manufacturer's test certificate M according to DIN 55350-18 (Zwick-Maximum gross force 1.45 JkN) for the measurement (all these are devices of the company Zwick GmbH &Co. KG, Ulm, Germany) with the order number BTC-FR 2.5 TH. D09 for the machine for testing, the order number BTC-LC 0050N. For the force gauge exercised, the order number BO 70000 S06 for the centering system.

BRIEF DESCRIPTION OF THE FIGURE Figure 1 shows the measurement of the hardness of a tablet, especially the device (6) for adjusting the tablet (4) used before and during the measurement. To this end, the tablet (4) is fixed between the upper pressure plate (1) and the lower pressure plate (3) of the device for exerting force not shown with the help of two fastening devices composed of two parts, which are fixed each to the upper or lower pressure plates after adjusting the distance (5) required for the taking and for centering the tablet used for the measurement. For the adjustment of the distance (5) the clamping devices, composed of two parts, can move horizontally outwards or inwards on the pressure plate on which they rest, respectively.

DETAILED DESCRIPTION OF THE INVENTION Tablets which have not been broken, but which have optionally undergone plastic deformation by force action, are also classified as resistant to breaking under a specific load.

In the administration forms obtained according to the invention, the hardness is measured according to the indicated method, also examining the administration forms that are not compressed. The invention is explained below by means of examples. These explanations are only by way of example and do not restrict the general concept of the invention. Examples: Tramadol hydrochloride was used as an active ingredient in a series of examples. Tramadol hydrochloride was used, although tramadol is not an active substance with potential for conventional abuse, because it is not subject to German legislation on narcotics, but for which experimental work is simplified. In addition, tramadol is a representative of the class of opioids with excellent water solubility.

Example 1 Components For each tablet Total basic mixture 100 mg Hydrochloride 100 g tramadol Poly (200 mg ethylene oxide 200 g), NF, MW 7 000 000 (Poiyox WSR 303, Dow Chemicals) Total weight 300 mg 300 g The tramadol hydrochloride and the poly (ethylene oxide) powder were mixed in a free fall mixer. A compression tool with upper mold was heated, lower mold and matrix for tablets with a diameter of 10 mm and a radius of curvature of 8 mm at 80 ° C in a heating cabinet. By means of the heated instruments, 300 mg portions of the powder mixture were compressed each time, the pressure being maintained for at least 15 s by clamping the compression instruments in a lathe. The hardness of the tablets was determined with the indicated apparatus according to the indicated method. The tablets did not break when exposed to a force of 500 N.

The tablet could not be crushed with a hammer. Nor was it possible with the help of a mortar and pestle. The in-vitro release of the active ingredient was determined from the preparation in a shoveling apparatus according to the European Pharmacopoeia. The temperature of the release medium was 37 ° C and the rotation speed of the agitator 75 min "1. At the beginning of the investigation, each tablet was placed in 600 ml of artificial gastric juice with a pH of 1.2. 30 minutes, the pH value <pH was increased to 2.3 by the addition of an alkaline solution, after a further 90 minutes until pH 6.5 and after a further 60 minutes until pH 7.2. liberated present in the dissolution medium at each point in time was determined by spectrophotometry.

EXAMPLE 2 300 mg portions of the powder mixture of Example 1 were heated to 80 ° C and introduced into the matrix of the compression instruments. The compression was then carried out. The tablet has the same properties as the tablet prepared according to example 1 Example 3 Tramadol hydrochloride and the components indicated above were mixed in a free fall mixer. A compression tool with upper mold, lower mold and matrix for tablets with a diameter of 7 mm at 80 ° C was heated in a heating cabinet. 150 mg portions of the powder mixture were compressed by means of the heated instruments, the pressure being maintained for at least 15 s by clamping the compression instruments in a lathe.

The hardness of the tablets was determined with the indicated apparatus according to the indicated method. The tablets were not broken when exposed to a force of 500 N. The in-vitro release of the active principle was determined as in Example 1 and was found to be: Example 4 Tramadol hydrochloride, xanthan and poly (ethylene oxide) were mixed in a free fall mixer. A compression tool with upper mold, lower mold and matrix for tablets with a diameter of 10 mm and a radius of curvature of 8 mm at 80 ° C was heated in a heating cabinet. 300 mg portions of the powder mixture were compressed by means of the heated instruments, the pressure being maintained for at least 15 s by clamping the compression instruments in a lathe. The hardness of the tablets was determined with the indicated apparatus according to the indicated method. The tablets did not break when exposed to a force of 500 N. The tablets suffered a small plastic deformation. The in-vitro release of the active principle was determined from the preparation as in Example 1 and was found to be: The tablets could be cut with a knife into pieces with a edge length of up to about 2 mm. Further comminution until spraying was not possible. When the pieces were combined with water, a highly viscous gel is formed. Only with great difficulty could the gel be pressed through an injection needle : 5 of 0.9 mm. When the gel was injected into water, the gel did not mix spontaneously with water, but continued to be visually distinguishable.

Example 5 10 Tramadol hydrochloride, xanthan and poly (ethylene oxide) were mixed in a free fall mixer. A compression tool with upper mold, lower mold and matrix for oblong tablets 10 mm long and 5 mm wide at 90 ° C was heated in a heating cabinet. 150 mg portions of the powder mixture were compressed by means of the heated instruments, the pressure being maintained for at least 15 s by clamping the compression instruments in a lathe. The hardness of the tablets was determined with the indicated apparatus according to the indicated method. The tablets did not break when exposed to a force of 500 N. The tablets suffered a small plastic deformation. The in-vitro release of the active principle was determined from the preparation as in Example 1 and was found to be: The tablets could be cut into pieces with a edge length of up to about 2 mm, but could not be sprayed. When the pieces were combined with water, a highly viscous gel was formed. Only with great difficulty could the gel be pressed through a 0.9 mm injection needle. When the gel was injected into water, the gel did not mix spontaneously with water, but continued to be visually distinguishable.

Example 6 A tablet with the following composition was prepared as described in example 1: The release of the active principle was determined as follows: The in-vitro release of the active ingredient from the tablet was determined in a shoveling apparatus according to the European Pharmacopoeia. The temperature of the release medium was 37 ° C and the rotation speed 75 U per minute. Phosphate buffer, pH 6.8, described in the USP served as release medium. The amount of active principle present in the solvent was determined at each point in the time of measurement by spectrophotometry.

The hardness of the tablets was determined with the indicated apparatus according to the indicated method. The tablets did not break when exposed to a force of 500 N. The tablets could be cut into pieces with a edge length of up to about 2 mm, but could not be sprayed. When the pieces were combined with water, a highly viscous gel was formed. Only with great difficulty could the gel be pressed through a 0.9 mm injection needle. When the gel was injected into water, the gel did not mix spontaneously with water, but continued to be visually distinguishable.

Example 7 The amount of BHT indicated in ethanol (96%) was dissolved, so that an ethanolic solution of 7.7% (% m / m) was obtained. This was mixed with the poly (ethylene oxide) and then dried at 40 ° C for 12 hours. All remaining components were added to the dried mixture and mixed in a free fall mixer for 15 min.

The preparation of the tablets was carried out according to the process described in example 1. Round molds (10 mm in diameter) with a radius of curvature of 8 mm were used. The hardness of the tablets was determined according to the method described above. The tablets did not break when exposed to a force of 500 N. The tablet could not be crushed using a hammer, or with the aid of a mortar and pestle. The in-vitro release of the active principle was carried out from the administration form according to the indications given in example 1 for the determination of the release.

Example 8 The individual components were mixed in a free fall mixer for 15 minutes. The preparation of the tablets according to example 1 was carried out with hot compression instruments. Round molds (10 mm diameter) with a radius of curvature of 8 mm were used. The hardness of the tablets was determined according to the method described. The tablets did not break when exposed to a force of 500 N. The tablet could not be broken up using a hammer, or with the aid of a mortar and pestle. The in-vitro release of the active principle was determined from the preparation in the manner indicated in example 1.

Claims (30)

1. CLAIMS 1. Form of administration thermoformed without extrusion, abuse-proof, characterized in that it has, in addition to one or more active principles (A) susceptible to abuse, as well as optionally physiologically acceptable auxiliary substances (B), at least one polymer (C) ) synthetic or natural and optionally at least one wax (D), the component (C) and the component (D) optionally having a hardness of at least 500 N.
2. 2. Form of administration according to claim 1, characterized in that it is presented in the form of a tablet.
3. 3. Form of administration according to claim 1, characterized in that it is in the form of multiple particles, preferably in the form of microcompides, micropellets, granules, spheroids, beads or pellets, optionally compacted in tablets or filled in capsules. Form of administration according to one of claims 1 to 3, characterized in that it contains as polymer (C) at least one polymer selected from the group comprising polyethylene oxide, polymethylene oxide, polypropylene oxide, polyethylene, polypropylene, poly (chloride) of vinyl), polycarbonate, polystyrene, polyacrylate, copolymers and mixtures thereof, preferably polyethylene oxide. 5. Form of administration according to one of claims 1 to 4, characterized in that the polyethylene oxide (C) has a molecular weight of at least 0.5 million. 6. Method of administration according to the claim 5, characterized in that the molecular weight of the polyethylene oxide (C) is at least 1 million. 7. Method of administration according to the claim 6, characterized in that the molecular weight of the polyethylene oxide (C) is from 1 to 15 million. Form of administration according to one of claims 1 to 7, characterized in that it contains as wax (D) at least one natural, semi-synthetic or synthetic wax with a softening point of at least 60 ° C. 9. Method of administration according to claim 8, characterized in that the wax (D) is carnauba wax or beeswax. 10. Method of administration according to one of claims 1 to 9, characterized in that the component (s) (C) and optionally (D) is (are) present in amounts such that the administration form has a Hardness of at least 500 N. 11. Method of administration according to one of claims 1 to 10, characterized in that the active principle (A) is at least one active principle selected from the group comprising opioids, tranquilizers, stimulants, barbiturates and other narcotics. . Form of administration according to one of claims 1 to 11, characterized in that it additionally has at least one of the following components a) -f): (a) at least one substance that irritates the nasal passages and / or the pharynx, ( b) at least one agent that increases the viscosity, which with the aid of a minimum necessary amount of an aqueous liquid forms a gel with the extract obtained from the administration form, which preferably remains visually distinguishable when added to an additional amount of aqueous liquid, (c) at least one antagonist for the active substance or active substances susceptible to abuse, (d) at least one emetic, (e) at least one dye as an aversive agent, (f) at least one bitter substance. 13. Method of administration according to claim 12, characterized in that the irritant substance according to component (a) causes a stinging, an itching, an impulse to sneeze, an increase in secretions or a combination of at least two of these stimuli. 14. Form of administration according to claim 12 or 13, characterized in that the irritant substance according to component (a) is based on one or more constituents of at least one drug with spicy substances. 15. Method of administration according to claim 14, characterized in that the drug with spicy substances is at least one drug selected from the group comprising Allii sativi Bulbus., Asari Rhizoma c. Herba, Calami Rhizoma, Capsici Fructus (pepper), Capsici Fructus acer (chilli pepper), Curcumae longae Rhizoma, Curcumae xanthorrhizae Rhizoma, Galangae Rhizoma, Myristicae Semen, Piperis nigri Fructus (pepper), Sinapis albae (Erucae) Semen, Sinapis nigri Semen, Zedoariae Rhizoma and Zingiberis Rhizoma, especially preferably at least one drug selected from the group comprising Capsici Fructus (pepper), Capsici Fructus acer (chilli pepper) and Piperis nigri Fructus (pepper). Form of administration according to one of claims 14 or 15, characterized in that the constituent of the drug with spicy substances is present as an o-methoxy (methyl) phenol compound, an acid amide compound, a mustard essence or a sulfide compound, or is derived from one such compound. 17. Method of administration according to one of claims 14 to 16, characterized in that the constituent of the drug with spicy substances is at least one constituent selected from the group comprising iristicin, elemycin, isoeugenol, β-asarone, safrole, gingerols, xantorizol, capsaicinoids, preferably capsaicin, piperine, preferably trans-piperine, glucosinolates, preferably based on non-volatile mustard essences, especially preferably based on mustard essence with p-hydroxybenzyl substituents, mustard essence with methyl mercapto substituents or mustard essence with methylsulfonyl substituents, and compounds derived from these constituents. 18. Method of administration according to one of claims 12 to 17, characterized in that the component (b) is at least one agent that increases the viscosity selected from the group comprising microcrystalline cellulose with 11% by weight of sodium carboxymethylcellulose (Avicel "RC591 ), sodium carboxymethylcellulose (Blanose®, CMC-Na C300P®, Frimulsion BLC-S®, Tylose C300 P), polyacrylic acid (Carbopol0 980 NF, Carbopol "3 981), carob bean meal (Cesagum0 LA-200, Cesagum8) LID / 150, Cesagum "LN-1), citrus or apple pectins (Cesapectin" HM Medium Rapid Set), waxy corn starch (C * Gel 04201®), sodium alginate (Frimulsion ALG (E401) @), flour of guar seeds (Frimulsion BM, Polygum 26 / 1-75T), iota-carrageenan (Frimulsion D021®), karaya gum, gellan gum (Kelcogel F®, Kelcogel LT100®), galactomannan (Meyprogat 150 *), seed meal tara (Polygum 43 / 1®), propylene glycol alginate (Protanal-Ester SD-LB0), sodium hyaluronate ico, tragacanth, tara gum (Vidogum SP 200ß), fermented polysaccharides of welan gum (K1A96) and xantan gum (Xantural 180). 19. Method of administration according to one of claims 12 to 18, characterized in that the component (c) is at least one opioid antagonist selected from the group comprising naloxone, naltrexone, nalmefene, nalid, nalmexone, nalorphine, nalbuphine and a corresponding physiologically acceptable, especially a base, a salt or solvate. 20. Method of administration according to one of claims 12 to 18, characterized in that the component (c) is at least one neuroleptic as a stimulant antagonist, preferably selected from the group comprising haloperidol, promethazine, flufenacin, perphenazine, levomepromazine, thioridazine, peracin. , chlorpromazine, chlorprothixene, zuclopenthixol, flupentixol, protipendil, zotepine, benperidol, pipamperone, melperone and bromoperidol. 21. Method of administration according to one of claims 12 to 20, characterized in that the emetic according to component (d) is based on one or more constituents of Radix Ipecacuanhae (ipecac root), preferably based on the constituent emetine, and / or is apo orphine 22. Administration form according to one of claims 12 to 21, characterized in that component (e) is at least one physiologically acceptable dye. 23. Method of administration according to one of claims 12 to 22, characterized in that the component (f) is at least one bitter substance selected from the group comprising aromatic essences, preferably mint essence, eucalyptus essence, bitter almond essence, menthol and the mixtures thereof, fruit aromatic substances, preferably of lemons, oranges, limes, grapefruit and mixtures of at least two components thereof, denatonium benzoate and mixtures of at least two components thereof. 24. Method of administration according to one of claims 12 to 23, characterized in that the active principle or active principles (A) are / are spatially separated from component (c) and / or (d) and / or (f), preferably without direct contact, the active ingredient or active ingredients (A) being found in at least one subunit (X) and the components (c) and / or (d) and / or (f) in at least one subunit (Y), and that, when the form of administration is administered correctly, the components (c) and / or (d) and / or (f) of the subunit (Y) do not produce their effect during the taking and / or in the organism. 25. Method of administration according to one of claims 1 to 24, characterized in that it contains at least one active ingredient at least partially in the form of controlled release. 26. Method of administration according to claim 25, characterized in that each of the active principles (A) susceptible to abuse is in a controlled release matrix. 27. Method of administration according to claim 26, characterized in that the component (C) and / or the optionally present component (D) also serves as a controlled release matrix material. Process for the preparation of a method of administration according to one of claims 1 to 27, characterized in that, without the use of an extruder, the components (A), (B), (C) and the optionally present component (D) are mixed. , as well as the components (a) to (f) optionally present together, or, whenever necessary, separately with addition of the component (C) and optionally (D), and the resulting mixture or mixtures are molded optionally resulting after a granulation, under exposure to the previous or simultaneous heat, to give rise to the administration form. Process according to claim 28, characterized in that the granulation is carried out according to wet or melt granulation. 30. Method of administration according to one of claims 1 to 27, which is obtained by a process according to claims 28 or 29.